NCT02124902View on ClinicalTrials.gov

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

PHASE2TerminatedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

July 7, 2014

Primary Completion Date

November 10, 2021

Study Completion Date

December 31, 2021

Conditions
Triple Negative Breast Neoplasms
Interventions
DRUG

Docetaxel

DRUG

Carboplatin

PROCEDURE

FDG-PET/MR

"* Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study"

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Breast Cancer Research Foundation

OTHER

collaborator

NeoImmuneTech

INDUSTRY

lead

Washington University School of Medicine

OTHER